Gentler preparation before stem cell transplant for non-cancer blood and immune disorders
Tests a gentler preparation before stem cell transplant in young people with non-cancer disorders.
Key facts
- Who runs it
- Paul Szabolcs
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 4 Feb 2014
- Expected to end
- Nov 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Hydroxyurea
- Alemtuzumab
- Fludarabine
- Melphalan
- Thiotepa
- Record updated
- 15 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults with a non-malignant (non-cancer) disease that a stem cell transplant can treat, such as an immune deficiency, bone marrow failure, inherited metabolic disease, hereditary anemia or Crohn's disease. A reduced-intensity conditioning regimen is given before the transplant.
- Age
- From 2 Months to 55 Years.
- Sex
- All sexes can join.
- Disease stage
- A non-malignant disorder that can be treated with stem cell transplant. Sickle cell disease needs one or more of: stroke, 2 or more pain crises per year, acute chest syndrome, osteonecrosis of 1 or more joints, or priapism.
- Earlier treatment
- No donor stem cell transplant in the previous 6 months. A suitable donor graft must be available: a cord blood unit, or an 8 of 8 or 7 of 8 HLA-matched unrelated donor bone marrow or blood stem cell graft.
- Biomarker or test result
- HIV negative. Negative pregnancy test for those who are pubertal or menstruating. Kidney, liver, heart and lung tests must show adequate function.
Main reasons for not taking part
- Any active cancer or MDS
- Severe acquired aplastic anemia
- Uncontrolled bacterial, viral or fungal infection
- Pregnancy or nursing mother
- Poorly controlled pulmonary hypertension
The registry criteria, word for word
Show all 14 criteriaShow less
Other criteria
- Inclusion:
- A 4/6, 5/6 or 6/6 HLA matched related or unrelated UCB unit available that will deliver a pre-cryopreservation total nucleated cell dose of ≥ 3 x 10e7 cells/kg, or double unit grafts, each cord blood unit delivering at least 2 x 10e7 cells/kg OR an 8 of 8 or 7 of 8 HLA allele level matched unrelated donor bone marrow or peripheral blood progenitor graft
- Adequate organ function as measured by:; Creatinine ≤ 2.0 mg/dL and creatinine clearance ≥ 50 mL/min/1.73 m2; Hepatic transaminases (ALT/AST) ≤ 4 x upper limit of normal (ULN); Adequate cardiac function by echocardiogram or radionuclide scan (shortening fraction > 26% or ejection fraction > 40% or > 80% of normal value for age); Pulmonary evaluation testing demonstrating CVC or FEV1/FVC of ≥ 50% of predicted for age and/or resting pulse oximeter ≥ 92% on room air or clearance by the pediatric or adult pulmonologist. For adult patients DLCO (corrected for hemoglobin) should be ≥ 50% of predicted if the DLCO can be obtained
- Written informed consent and/or assent according to FDA guidelines
- Negative pregnancy test if pubertal and/or menstruating
- HIV negative
- A non-malignant disorder amenable to treatment by stem cell transplantation, including but not limited to:; Primary Immunodeficiency syndromes including but not limited to:; Severe Combined Immune Deficiency (SCID) with NK cell activity; Omenn Syndrome; Bare Lymphocyte Syndrome (BLS); Combined Immune Deficiency (CID) syndromes; Combined Variable Immune Deficiency (CVID) syndrome; Wiskott-Aldrich Syndrome; Leukocyte adhesion deficiency; Chronic granulomatous disease (CGD); X-linked Hyper IgM (XHIM) syndrome; IPEX syndrome; Chediak - Higashi Syndrome; Autoimmune Lymphoproliferative Syndrome (ALPS); Hemophagocytic Lymphohistiocytosis (HLH) syndromes; Lymphocyte Signaling defects; Other primary immune defects where hematopoietic stem cell transplantation may be beneficial; Congenital bone marrow failure syndromes including but not limited to:; Dyskeratosis Congenita (DC); Congenital Amegakaryocytic Thrombocytopenia (CAMT); Osteopetrosis; Inherited Metabolic Disorders (IMD) including but not limited to:; Mucopolysaccharidoses; Hurler syndrome (MPS I); Hunter syndrome (MPS II); Leukodystrophies; Krabbe Disease, also known as globoid cell leukodystrophy; Metachromatic leukodystrophy (MLD); X-linked adrenoleukodystrophy (ALD); Hereditary diffuse leukoencephalopathy with spheroids (HDLS); Other inherited metabolic disorders; alpha mannosidosis; Gaucher Disease; Other inheritable metabolic diseases where hematopoietic stem cell transplantation may be beneficial; Hereditary anemias; Thalassemia major; Sickle cell disease (SCD) - patients with sickle disease must have one or more of the following:; Overt or silent stroke; Pain crises ≥ 2 episodes per year for past year; One or more episodes of acute chest syndrome; Osteonecrosis involving ≥ 1 joints; Priapism; Diamond Blackfan Anemia (DBA); Other congenital transfusion dependent anemias; Inflammatory Conditions; Crohn's Disease/Inflammatory Bowel Disease; Exclusion:
- Allogeneic hematopoietic stem cell transplant within the previous 6 months
- Any active malignancy or MDS
- Severe acquired aplastic anemia
- Uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression of clinical symptoms)
- Pregnancy or nursing mother
- Poorly controlled pulmonary hypertension
- Any condition that precludes serial follow-up
Where in United States
- UPMC Children's Hospital of PittsburghPittsburgh, United StatesContact: Shawna McIntyre, RNTaking people
About the trial
What the trial wants to find out
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.
The 2 groups in the trial
- UCBT:transfusion dependent anemias or increased rejection riskTreatment being tested
Alemtuzumab, Hydroxyurea, Fludarabine, Melphalan, and Thiotepa conditioning regimen prior to allogenic HSCT.
Treatment: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, and Thiotepa
- BMT, PBSCT and not transfusion dependent UCBTTreatment being tested
Alemtuzumab, Hydroxyurea, Fludarabine, Melphalan, and Thiotepa conditioning regimen prior to allogenic HSCT.
Treatment: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, and Thiotepa
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
- Plain-language title
- Gentler preparation before stem cell transplant for non-cancer blood and immune disordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 December 2025